After Today’s Bullish Options Activity, Is bluebird bio Inc’s Near-Term Analysis Positive?

 After Today's Bullish Options Activity, Is bluebird bio Inc's Near Term Analysis Positive?

In today’s session bluebird bio Inc (BLUE) registered an unusually high (320) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious BLUE increase. With 320 contracts traded and 9834 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: BLUE161216C00075000 closed last at: $1.85 or 19.4% up. About 3.40M shares traded hands or 155.64% up from the average. bluebird bio Inc (NASDAQ:BLUE) has risen 33.84% since April 28, 2016 and is uptrending. It has outperformed by 27.92% the S&P500.

Analysts await bluebird bio Inc (NASDAQ:BLUE) to report earnings on February, 22. They expect $-1.84 EPS, down 42.64% or $0.55 from last year’s $-1.29 per share. After $-2.07 actual EPS reported by bluebird bio Inc for the previous quarter, Wall Street now forecasts -11.11% EPS growth.

bluebird bio Inc (NASDAQ:BLUE) Ratings Coverage

Out of 14 analysts covering bluebird bio (NASDAQ:BLUE), 10 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 71% are positive. $244 is the highest target while $14 is the lowest. The $108.27 average target is 58.29% above today’s ($68.4) stock price. bluebird bio has been the topic of 29 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Friday, October 23 by Jefferies. As per Thursday, September 22, the company rating was initiated by Roth Capital. Roth Capital initiated bluebird bio Inc (NASDAQ:BLUE) rating on Thursday, December 3. Roth Capital has “Buy” rating and $121 price target. The firm has “Outperform” rating given on Tuesday, October 20 by Oppenheimer. The firm has “Neutral” rating by Bank of America given on Monday, December 7. The firm earned “Buy” rating on Friday, August 28 by Roth Capital. TH Capital initiated bluebird bio Inc (NASDAQ:BLUE) rating on Thursday, December 3. TH Capital has “Buy” rating and $121 price target. The stock has “Equal-Weight” rating given by Morgan Stanley on Tuesday, September 8. The rating was maintained by Maxim Group on Tuesday, January 5 with “Buy”. The stock of bluebird bio Inc (NASDAQ:BLUE) has “Overweight” rating given on Monday, October 5 by Morgan Stanley.

According to Zacks Investment Research, “Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment increased to 1.48 in Q2 2016. Its up 0.48, from 1 in 2016Q1. The ratio improved, as 29 funds sold all bluebird bio Inc shares owned while 52 reduced positions. 20 funds bought stakes while 61 increased positions. They now own 42.29 million shares or 3.30% more from 40.94 million shares in 2016Q1.
Manufacturers Life Insurance The has invested 0% of its portfolio in bluebird bio Inc (NASDAQ:BLUE). Qvt Financial Ltd Partnership has 59,002 shares for 0.18% of their US portfolio. Tocqueville Asset Mgmt Ltd Partnership holds 0.03% or 52,800 shares in its portfolio. State Board Of Administration Of Florida Retirement holds 0% of its portfolio in bluebird bio Inc (NASDAQ:BLUE) for 22,670 shares. Glenmede Trust Na reported 155 shares or 0% of all its holdings. Williams Jones Assoc Limited Liability has 0.01% invested in the company for 5,850 shares. Renaissance Lc has 82,500 shares for 0.01% of their US portfolio. Ameriprise Inc, a Minnesota-based fund reported 79,002 shares. Northern Tru Corp has 0.01% invested in the company for 404,141 shares. Great West Life Assurance Company Can last reported 0% of its portfolio in the stock. Blackrock Inv Ltd Company holds 146,840 shares or 0.01% of its portfolio. Panagora Asset Mngmt owns 2,227 shares or 0% of their US portfolio. Jane Street Grp Ltd has 0% invested in the company for 9,819 shares. Moreover, Creative Planning has 0.01% invested in bluebird bio Inc (NASDAQ:BLUE) for 25,801 shares. Sivik Healthcare Ltd Company has invested 0.43% of its portfolio in bluebird bio Inc (NASDAQ:BLUE).

bluebird bio, Inc. is a biotechnology company. The company has a market cap of $2.39 billion. The Firm is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell immunotherapy. It currently has negative earnings. The Company’s gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

BLUE Company Profile

bluebird bio, Inc., incorporated on April 16, 1992, is a biotechnology company. The Firm is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell immunotherapy. With its lentiviral gene therapies, T cell immunotherapy expertise and gene editing capabilities, it offers an integrated product platform with application in severe genetic and rare diseases, and in oncology. The Company’s gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. The Company’s oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. The Company’s oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

More notable recent bluebird bio Inc (NASDAQ:BLUE) news were published by: Fool.com which released: “Why bluebird bio, Inc. Stock Is Soaring Today” on December 01, 2016, also Fool.com with their article: “Why bluebird bio Inc. Got Knocked Down Today” published on November 03, 2016, Fool.com published: “Why bluebird bio Inc. Stock Jumped Today” on November 14, 2016. More interesting news about bluebird bio Inc (NASDAQ:BLUE) were released by: Fool.com and their article: “Why bluebird bio, Inc. Stock Got Crushed in October” published on November 10, 2016 as well as Benzinga.com‘s news article titled: “Heat Biologics Cools Off, Bluebird Bio Heats Up” with publication date: December 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment